Foley Hoag LLP has announced that partners Pat Cerundolo, Bryant Godfrey and Erin Estey Hertzog have been named Co-Chairs of the firm’s Healthcare Department.
“Healthcare constitutes more than one-sixth of the U.S. economy, and Foley Hoag continues to be integrally involved in every single major issue affecting the sector,” said Managing Partner Jim Bucking. “Pat, Bryant and Erin will lead the Healthcare Department in providing exceptional service to our healthcare provider, healthcare payer and FDA-regulated clients. Their depth of experience in key areas of support, including CMS and insurance regulatory matters, FDA strategy, and drug pricing and delivery, will help the group provide seamless, cross-disciplinary support across the market.”
Attorneys within Foley Hoag’s Healthcare Department support entities across the healthcare and life sciences spectrum, such as physicians and medical groups; home health agencies; payers, including Medicare Advantage and Part D plans, and commercial insurers; employee and health benefit managers; digital health, pharmaceutical and diagnostics companies; medical device manufacturers; and healthcare trade associations.
Cerundolo has an extensive background representing biopharmaceutical clients and industry trade associations in a wide range of state legislative and regulatory initiatives, including drug product access in the public and private payor environment, drug price transparency laws, physician marketing laws, and value-based arrangements. His knowledge of the intricacies of state-level policymaking reflects three years of experience in the Office of the General Counsel at the Commonwealth of Massachusetts Executive Office for Administration and Finance, where he focused on a range of legislative initiatives as well as general regulatory matters overseen by that agency.
Godfrey, who Co-Chairs the firm’s FDA Practice Group, provides strategic regulatory advice to large pharmaceutical, medical device and biotech companies, startups, and trade associations, helping them to navigate challenges relating to the development, manufacturing, approval and promotion of drugs, biologics, medical devices, and combination products. Godfrey spent nearly a decade at the U.S. Food and Drug Administration (FDA) in senior regulatory and policy roles. While at FDA, he was Senior Lead Regulatory Counsel in the Center for Drug Evaluation and Research, Office of Medical Policy, Office of Prescription Drug Promotion (OPDP), and was Senior Counsel/Special Assistant to the Principal Deputy Commissioner.
Hertzog advises clients regarding system delivery reform and value-based payment models; coding, coverage, payment, and drug pricing issues for innovative new technologies; and legal and regulatory issues before the U.S. Department of Health & Human Services (HHS) Office of the General Counsel. Since its enactment in 2022, she has earned a reputation as a leading authority on the Drug Price Negotiation provisions of the Inflation Reduction Act. Hertzog joined the firm from the CMS Division of the HHS Office of the General Counsel, where she was the lead attorney for the Center for Medicare and Medicaid Innovation (CMMI).
About Foley Hoag LLP
Foley Hoag is an award-winning, mid-sized, international law firm that focuses on innovative industries and high-stakes litigation. The diverse backgrounds, perspectives and experiences of our lawyers and business services professionals contribute to the exceptional service we deliver to clients. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.
